Treatment of adolescent girls with polycystic ovary syndrome and insulin resistance
https://doi.org/10.20538/1682-0363-2018-2-13-20
Abstract
Aim. Polycystic ovary syndrome is a common cause of infertility. In addition, polycystic ovary syndrome is often associated with metabolic complications. In most women hyperandrogenic manifestations occur during puberty. Early detection of polycystic ovary syndrome and associated metabolic problems can solve the problem of puberty and prevent infertility, metabolic syndrome, and diabetes mellitus type 2 in women of reproductive age. One of the objectives of the study was to evaluate the effectiveness of the simultaneous use of a combined oral preparation (ethinyl estradiol + drospirenone) and metformin in adolescent girls with polycystic ovary syndrome.
Materials and methods. 113 adolescent girls with hyperandrogenism from 14 to 19 years were included. 32 of these girls aged 14–18 years with polycystic ovary syndrome were treated with medication ethinyl estradiol + drospirenone. Of these 32 patients, 20 girls with insulin resistance were obtained simultaneously with metformin. The following methods were used: examination, evaluation of hair (Ferriman-Gallwey score), pelviс ultrasound, determination of hormone status (LH, FSH, PRL, 17-OHP, E2 , TSH, DHEA-s, SHBG, T), glucose, insulin, and glucose tolerance test. The diagnostic technique used the Sultan C. criteria of polycystic ovary syndrome (2004).
Results.A reduction in the frequency characteristics after treatment was shown: of laboratory hyperandrogenism 90.6% , dermopathy 65.6% , insulin resistance 43.8%, hyperinsulinemia 18.8%, ultrasonic signs of PCOS 34.4%.
Conclusions. The study results confirm the efficacy of the treatment of polycystic ovary syndrome with insulin resistance during puberty by Low-dose combined oral preparation (0.03 mg ethinyl estradiol and 3 mg drospirenone) in combination with metformin.
About the Authors
E. M. Bogatyreva
Saint-Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
PhD, Assistant, Department of Obstetrics and Gynecology with the Course of Children’s Gynecology,
2, Litovskaya Str., Saint-Petersburg, 194353
G. A. Novik
Saint-Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
DM, Professor, Head of the Department of Paediatrics,
2, Litovskaya Str., Saint-Petersburg, 194353
References
1. Шилин Д.Е. Коррекция метаболических и ýндокринных нарушений при лечении гиперандрогении у девочек и девушек. Фарматека. 2003; 16: 51–58. [Shilin D.E. Correction of metabolic and endocrine disorders in the treatment of hyperandrogenism in girls and young women. Farmateka. 2003; 16: 51–58 (in Russ.)].
2. Дедов И.И., Андреева Е.Н. Синдром поликистозных яичников. Практические рекомендации для врачей. М.: ИТМ, 2009: 4–5. [Dedov I.I., Andreeva E.N., Karpova E.A. Polycystic ovary syndrome. M.: ITM Publ., 2009: 4–5 (in Russ.)].
3. Conway G.S. et al. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 1992; 37: 119–125.
4. Wild R.A., Alaupovic P., Parcer I.G. Lipid and apolipoprotein abnormalities in hirsute women. Am. G. Obstet. Gynecol. 1992; 166 (4): 1191–1196.
5. Гуркин Ю.А. Детская и подростковая гинекология. М.: МИА, 2009: 698. [GurkinYu.A. The children and adolescent gynecology. M.: MIA Publ., 2009: 698 (in Russ.)].
6. Кузнецова И.В. Гормональная терапия и контрацепция у женщин с избыточной массой тела. М.: ОРЖИН, 2009. [Kuznetsova I.V. Hormonal therapy and contraception in women with overweight. M.: ORZHIN, 2009 (in Russ.)].
7. Богатырева Е.М., Новик Г.А., Кутушева Г.Ф. Фенотипы и ýндотипы синдрома гиперандрогении у девочек-подростков. Лечащий врач. 2016; 2: 70–74. [Bogatyreva E.M., Novik G.A., Kutusheva G.F. Phenotype and endotipy of hyperandrogenism in adolescent girls. Lechashchiy vrach. 2016; 2: 70–74 (in Russ.)].
8. Чеботарева Ю.Ю. Некоторые аспекты применения препарата, содержащего дроспиренон + ýтинилýстрадиол, при формирующемся синдроме поликистозных яичников у девочек-подростков. Репродуктивное здоровье детей и подростков. 2009; 2: 35–43. [Chebotaryova Yu.Yu. Certain aspects of the drug with drospirenon+ethinylestradiol use in polycystic ovaries syndrome in adolescent girls. Reproduktivnoe zdorove detej i podrostkov. 2009; 2: 35–40 (in Russ.)].
9. Уварова Е.В. Патогенетические аспекты и современные возможности коррекции гиперандрогенных проявлений у девочек-подростков. Лечащий врач. 2008; 3: 75–89. [Uvarova E.V. Pathogenetic aspects and modern possibilities of correction of hyperandrogenic symptoms in adolescent girls. Lechashchiy vrach. 2008; 3: 75–89 (in Russ.)].
10. Мадянов И.В., Мадянова Т.С. Синдром поликистозных яичников у девочек-подростков: клинико-метаболические особенности и перспективы применения метформина. Практическая медицина. 2010; 4 (43): 86–90. [Madyanov I.V., Madyanova T.S. Polycystic ovary syndrome at adolescent girls: Clinical and metabolic features and prospects use of Metformin. Prakticheskaya medicina. 2010; 4 (43): 86–90 (in Russ.)].
11. Чубкин И.В. Метаболический синдром у девушек подросткового возраста: автореф. дис. … канд. мед. наук. СПб., 2007: 23. [Chubkin I.V. Metabolic syndrome in girls adolescence: abstract … сand. of мed. sciences.] Sant-Peterburg, 2007: 23 (in Russ.)].
12. Sultan C. Clinical expression of polycystic ovarian disease in the adolescent. Horm. Res. 2005; 64. (1): 4.
13. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop Group. / Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004. 81: 9–25.
Review
For citations:
Bogatyreva E.M., Novik G.A. Treatment of adolescent girls with polycystic ovary syndrome and insulin resistance. Bulletin of Siberian Medicine. 2018;17(2):13-20. (In Russ.) https://doi.org/10.20538/1682-0363-2018-2-13-20
Views:
2769
Email this article 